A single injection of the GLP-1 agonist exenatide after spinal cord injury in rats shifted macrophages toward an anti-inflammatory state and significantly improved hind limb motor function from day 7 onward.
Significant improvement from day 7Rats receiving exenatide after spinal cord injury showed significantly better hind limb motor function starting just one week post-injury
What the researchers found
Rats receiving 10 μg exenatide subcutaneously immediately after spinal cord contusion injury showed significantly higher BBB locomotor scores (measuring hind limb motor function) from day 7 after injury onward compared to controls.
The mechanism involved macrophage polarization: exenatide increased expression of M2 (anti-inflammatory) markers and anti-inflammatory interleukins while decreasing M1 (pro-inflammatory) markers and inflammatory cytokines. Immunohistochemistry confirmed significantly more M2 macrophages in the exenatide group by day 3 after injury, while M1 macrophage numbers did not differ between groups — indicating the drug promoted anti-inflammatory immune cells rather than simply suppressing all immune activity.
Why it matters
Spinal cord injury has very limited treatment options, and the secondary inflammatory damage that follows the initial trauma is a major contributor to permanent disability. Finding that an already-approved drug like exenatide can shift the immune response from destructive to protective opens a realistic path toward clinical testing — bypassing years of drug development that would be needed for a novel compound.
How the study worked
Rat spinal cord contusion model was used. The exenatide group received a single subcutaneous injection of 10 μg exenatide immediately after injury; controls received PBS. Macrophage polarization was assessed by quantitative RT-PCR (gene expression of M1/M2 markers and cytokines) and immunohistochemical staining. Motor function recovery was measured using the BBB (Basso, Beattie, Bresnahan) locomotor rating scale.
What this study cannot tell us
This was an animal study using a rat contusion model, which does not perfectly replicate human spinal cord injuries. Only a single dose of exenatide was tested, so optimal dosing and timing remain unknown. The number of animals per group was not specified in the abstract. Long-term outcomes beyond the observation period were not assessed, and the study did not examine whether repeated dosing might provide additional benefit.
How to read the evidence
This is a preclinical animal study using a rat spinal cord contusion model. While the results are promising and mechanistically supported by both gene expression and immunohistochemistry data, translation to human patients requires clinical trials.
When this study was published
Published in 2024, this is a very recent study contributing to the rapidly expanding literature on GLP-1 agonist neuroprotective effects beyond metabolic disease.
The bigger picture
GLP-1 receptor agonists continue to reveal unexpected benefits beyond blood sugar control. This study adds spinal cord injury neuroprotection to a growing list that includes cardiovascular protection, neuroprotection in Parkinson's and stroke, and kidney benefits. The common thread appears to be anti-inflammatory and cell-protective effects mediated through GLP-1 receptors expressed throughout the nervous system.
Questions still open
- Would repeated exenatide dosing after spinal cord injury provide greater or more sustained functional improvement?
- Can these findings translate to human spinal cord injury patients, given the differences between rat and human spinal cord biology?
- Do other GLP-1 agonists like semaglutide or liraglutide produce similar macrophage polarization effects after spinal cord injury?
Common questions
What are M1 and M2 macrophages and why does their balance matter after spinal cord injury?
Why would a diabetes drug help with spinal cord injury?
Read the original research
The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype.
Frontiers in neuroscience, 18, 1342944
Citation
Noguchi, Toshihiro; Katoh, Hiroyuki; Nomura, Satoshi; Okada, Keiko; Watanabe, Masahiko. (2024). The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype.. Frontiers in neuroscience, 18, 1342944. https://doi.org/10.3389/fnins.2024.1342944